This study evaluated whether cytoskeletal alterations during the ischemic conditions associated with kidney preservation could determine apoptosis. Cytoskeletal alterations are among the main effects of ischemia and may induce apoptosis. Rat kidneys were preserved in University of Wisconsin (UW) solution for 24 h. Some groups of animals underwent 45 min of warm ischemia (WI) to evaluate its effect on both the actin cytoskeleton and apoptosis (assessed by caspase-3 activity and TUNEL staining). Swinholide A (SwinA) and Latrunculin B (LB), two actin cytoskeletontargeted agents, were administered to assess the effect of direct actin disruption on apoptosis. Jasplakinolide (JP), a compound that stabilizes actin filaments, was administered to evaluate the effect of actin stabilization. Apoptosis was evaluated at 3 h of ex vivo reperfusion using the isolated perfused rat kidney (IPK) model.
Introduction
Cytoskeleton alterations have been reported to induce apoptosis in a variety of models. Actin cytoskeletal derangement promotes apoptosis in human airway epithelial cells 1 and in rat and porcine proximal tubule epithelial cells, in which chemically induced apoptosis is preceded by the disorganization of the F-actin cytoskeleton. 2, 3 During kidney transplantation ischemia/reperfusion (I/R) injury occurs as a consequence of graft harvesting, cold preservation, surgery, or previous undesired warm ischemic episodes (WI) and can compromise the viability of the organ Correspondence to: G. Hotter, Department of Experimental Pathology, IIBB-CSIC-IDIBAPS, C/Rosselló, 161, 7 planta, 08036, Barcelona, Spain. Tel.: +34-93-363-83-34; Fax: +34-93-363-83-01; e-mail: ghcbam@iibb.csic.es upon transplantation. 4, 5 It is known that ischemia triggers a complex series of biochemical events in which the cytoskeleton plays a central role. Specifically, in the ischemic kidney, the disruption of actin microfilaments leads to the loss of tubule cell polarity and to the redistribution of the basolateral membrane. 6 Additionally, the destruction of brush border microvilli is accompanied by the formation of apical membrane blebs. 7 The tight junction barrier opens 8 and cell-cell and cell-substrate adhesions are lost, resulting in tubule cell detachment from the basement membrane into the lumen. 9 These sublethally injured cells contribute to renal dysfunction. 10 Thus, any ischemic process involved in kidney transplantation could potentially induce cytoskeletal changes. Specifically WI 11 has been associated with the rapid rearrangement of the actin cytoskeleton in the proximal tubule cells, in which the severity of the process is dependent on the severity of the ischemia.
Another non-desired effect of kidney I/R injury is cell death by necrosis or apoptosis. 12 During renal transplantation-related events, apoptosis may start with cold preservation and increase during reperfusion 13, 14 or start in reperfusion, contributing to the development of graft dysfunction. 15, 16 As actin cytoskeleton modifications have induced apoptosis in other experimental models, 17 and since cytoskeletal alterations and apoptotic events have been described during renal ischemia, [13] [14] [15] [16] we hypothesized that cytoskeleton derangement (and more precisely actin disruption) could well cause apoptosis during ischemic processes related to kidney transplantation.
Cytoskeletal alterations can be reversed and do not automatically lead to cell death. 18 However, once the apoptotic program is initiated, cell death is highly likely. Therefore, studies that demonstrate that cytoskeletal manipulation in preservation (when the injury is reversible) may modify the apoptosis outcome are of particular interest.
In this study we evaluated whether: (i) cytoskeletal alterations during two different ischemic injuries related to kidney transplantation could induce apoptosis development in the tissue and (ii) whether further pharmacological modifications of actin cytoskeleton derangement could modify apoptosis.
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Materials and methods
Animals and anesthesia
The study was performed using male Wistar rats (Ifa Credo, Barcelona, Spain) weighing 250-300 g. The animals were anesthetized by IP injection of sodium pentobarbital (30 mg/kg) and placed in a supine position. Body temperature was maintained between 36 and 37
• C. All procedures were conducted under the supervision of our institution's Research Commission and followed European Union guidelines for the handling and care of laboratory animals.
Pharmacological cytoskeleton manipulation
Two different actin cytoskeletal disruptors were used: Swinholide A (SwinA) is a microfilament-disrupting marine toxin that stabilizes actin dimmers and severs actin filaments, and Latrunculin B (LB) sequesters actin from polymerization and promotes actin depolymerization. 19 As stabilizing agent we used Jasplakinolide (JP), a compound that stabilizes actin filaments by binding F-actin in vitro. 19 
Surgical techniques
Cold preservation with or without warm ischemia (WI).
The abdomen of the animal was opened by a midline incision with bilateral subcostal extensions. The left adrenal artery and the small lumbar arteries were tied off. Heparin (1000 U) was administered by IV puncture. A polyethylene catheter (PE-80) was inserted into the infrarenal aorta immediately after the occlusion of the suprarenal aorta. The kidneys were immediately flushed in situ with 8 mL of University of Wisconsin (UW) preservation solution at 4
• C (maximum pressure of 60 mmHg). The renal vein was then cannulated through the cava vein with a catheter (PE-150). The left kidney was immediately removed and placed in a recipient with 20 mL of UW at 4
• C for 24 h (cold ischemic storage). In the sham-operated rats (Sham), the same surgical procedures were performed but without cold storage.
Isolated perfused rat kidney model (IPK).
The perfusion system used the method described by Herrera et al. 20 with slight modifications. After the cold ischemia period, the kidney was placed in a perfusion chamber at a constant temperature (37.5 • C), and the renal artery cannula was connected to a recirculating system for 3 h. The perfusion fluid (total volume = 250 mL) was warmed up to 37.5
• C and oxygenated with a 95% O 2 /5% CO 2 mixture 2 h before the beginning of reperfusion, and it was kept under these conditions throughout the reperfusion period. The perfusate was delivered to the renal artery cannula through a peristaltic pump (Gilson Medical Electronics, Villiers-le-Bel, France) and filtered through a 0.5 µm pore-size filter (Millipore Corporation, Bedford, MA). Perfusion pressure was kept constant at 60 mmHg. Braun Medical, Rubi, Spain) supplemented with (in mM): tyrosine 0.2; lysine 0.6; glycine, 1.4; cysteine, 0.45 and glutamine, 2. Streptomycin (10 mg/L) and penicillin G (100,000 I.U./L) were used as antibiotic prophylaxis. All ingredients used were purchased from Sigma (Sigma-Aldrich Corporation, St. Louis, MO).
Experimental groups and protocols
Animals were randomly assigned to the following experimental groups (n = 6 each group):
Cold ischemia group. Kidneys were isolated and preserved for 24 h in UW solution.
Group 3 (CI + JP): Jasplakinolide-treated group. To evaluate the effects of F-actin stabilization, we administered Jasplakinolide (JP) (Calbiochem, La Jolla, CA) as a stabilizer agent. JP-treated kidneys followed the same procedure as those from the CI group but just before preservation they were flushed with 500 µl of UW containing 20 nM of JP. (This dose has proven to be effective in stabilizing actin in previous studies. 21 Groups 4 and 5 (CI + SwinA and CI + LB): Swinholide A-treated group and Latrunculin B-treated group. To evaluate the effects of direct disruption of actin cytoskeleton during preservation, two actin cytoskeleton disruptor agents-SwinA and LB (Sigma-Aldrich Corporation, St. Louis, MO)-were administered. The SwinA-treated kidneys followed the same procedure as those from the CI group but just before preservation they were flushed with 500 µl of UW containing 500 nM of SwinA. (This dose has proven to be effective in previous studies. 22 The LB-treated kidneys were flushed with 500 µl of UW containing 1 µM of LB. Previous studies have shown Latrunculin to be effective at concentrations between 0.5 and 1 µM 8.
21,23,24
Group 6 (CI + SwinA + JP): Swinholide A plus Jasplakinolide-treated group. To evaluate whether cytoskeletal stabilization was able to counteract the effects of a previous pharmacological disruption, JP was administered 10 min after SwinA infusion. Both substances were administered as described above (see groups 3 and 4).
Group 7 (WI + CI): Warm ischemia group. Kidneys underwent 45 min of WI before isolation and cold storage to evaluate the effects of warm ischemia.
Group 8 (WI + JP + CI): Warm ischemia plus Jasplakinolide administration group. To assess if cytoskeletal stabilization was able to counteract the effects of warm ischemia, JP (20 nM) was administered diluted in 1 mL of saline solution by direct puncture into the aorta just before WI. After 45 min of WI, the kidneys were preserved as described above.
Actin cytoskeleton and apoptosis assessment after 24 h of cold preservation. At the end of the preservation period, the kidneys were divided into three parts: one part was immediately freeze-clamped to determine caspase-3 activity; another was fixed in formalin 4% for TUNEL analysis, and the last part was embedded in optimum cutting temperature compound (OCT; Sakura Finetek USA, Inc., Torrance, CA) and frozen in liquid nitrogen for immunofluorescence procedures.
Apoptosis assessment in the IPK model. Kidneys underwent 3 h of ex vivo reperfusion after the preservation period and were then divided into two parts: one part was immediately freezeclamped to determine caspase-3 activity, and another part was fixed for TUNEL staining. These groups were given the same names as groups 1 to 7, with the letter "R" (reperfusion) added at the end (CI/R, WI+CI/R, CI/R+SwinA, CI/R+LB, CI/R+JP, WI+JP+CI/R, CI/R+SwinA+JP groups).
Biochemical analyses
Caspase-3 activity. Caspase-3 activity was determined by measuring the proteolytic cleavage of the specific substrate N-acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin (Ac-DEVD-AMC; Biomol, Plymouth Meeting, PA). 150 mg of the kidney was homogenized and sonicated in assay buffer (50 mM HEPES, 10% sucrose, 0.1% CHAPS, 5 mM oxidized glutathione, 5 mM dithiothreitol, 1 mM PMSF; pH 7.4). We used 250 µg of protein of each sample and 50 µM Ac-DEVD-AMC to perform the assay. The AMC released was quantified for 2 h at 37
• C by fluorospectrophotometry using 380 nm excitation and measurement of 450 nm emission.
Immunohistological procedures
Confocal microscopy analyses. One half of the kidney was embedded in OCT and frozen in liquid nitrogen without prior fixation. 5-µm cryosections were fixed in 4% buffered formaldehyde for 10 min and then permeabilized with PBS containing 0.1% Triton X-100 and 1% BSA during 30 min. For actin visualization the slides were incubated with Alexa Fluor 568-phalloidin (Molecular Probes Inc., Eugene, OR) (dilution, 1:40) in PBS with 1% BSA during 30 min. Slides were washed three times for 15 min with PBS, and finally mounted using mowiol (Calbiochem, La Jolla, CA). Confocal images were taken with a Leica TCS NT laser microscope (Leica Microsystems, Wetzlar, Germany) equipped with a 100× oil-immersion objective.
TUNEL staining. Cell death was detected by enzymatic labeling of DNA strand breaks using the ApopTag peroxidase In situ Apoptosis Detection Kit (Intergen Company, NY) following the manufacturer's instructions. In brief, 3-µm sections were deparaffinized, rehydrated and treated with proteinase K (20 µg/mL) for 30 min. After washing, the endogenous peroxidase was quenched with 3% hydrogen peroxide in PBS for 5 min followed by further washing. The labeling reaction was performed following the manufacturer's instructions. Finally, slides were developed by the addition of diaminobenzidine chromogen substrate for 5 min, counterstained with hematoxylin and coverslipped. Twenty-five fields were randomly selected in each section (magnification × 400), in which the number of apoptotic cells was counted and expressed as a percentage of positive tubular cells. Tubular cells were considered positive when dark-stained nuclei were observed.
Statistical analyses
Data are expressed as means ± SEM. Means of different groups were compared using one-way ANOVA. The Student-Newman-Keuls test was used for the evaluation of significant differences between groups. Significant differences were assumed when P < 0.05.
Results
Actin cytoskeleton derangement and apoptosis during ischemia Figure 1 shows images of fluorescent F-actin in proximal tubule epithelial cells in the different groups.
As previously described, normal rat kidneys (sham group) showed intense actin staining in the apical brush border microvilli of proximal tubule epithelial cells, as well as in distinct bundles associated with the basal plasma membrane of the cells. 25 After CI, cytoskeletal alterations were detected; in this group the F-actin pattern was less intense in the bundles associated with the plasma membrane. The cytoskeletal stabilizer JP (CI+JP group) demonstrated its effectiveness by stabilizing the actin cytoskeleton and showed a better preservation of F-actin distribution.
The effect of the cytoskeletal disruptors Latrunculin and Swinholide-A was shown by a decrease in brush border F-actin staining. Though with Lantruculine not all the tubules showed the same F-actin intensity (some showed well preserved F-actin, and others a strong decrease), the results demonstrate this agent's effectiveness. The addition of JP to the groups with distribution altered by Swinholide (CI+SwinA+JP group) reversed the actin cytoskeleton disruption, as evidenced by an increase in F-actin staining in the microvilli and in the intensity of the actin associated with the plasma membrane, thus demonstrating the ability of the stabilizer to reverse the action of a cytoskeleton disruptor.
Prior WI enhanced the cytoskeleton alterations produced by cold ischemia, evidenced by a marked disruption of brush border actin together with a diffuse pattern in the actin associated with the plasma membrane (WI+CI group). Addition of JP reversed the actin cytoskeletal disruption previously induced by warm ischemia.
Caspase-3 activity is shown in Figure 2 . By the end of the preservation period it was not significantly modified in any of the treatments nor in cold ischemic treated groups with or without previous warm ischemia.
Similarly, TUNEL assessment at the end of ischemia (Figure 3) showed that there was no increase in DNA fragmentation due to cold ischemia: the CI group showed only occasional TUNEL-positive cells. Slight differences with respect to the CI group were reported only in the WI groups (WI+CI and WI+JP+CI), which showed some cortical tubules with TUNEL-positive staining.
To summarize, this first set of results indicates that the ischemic process per se provokes cytoskeleton disruption, but only very low levels of apoptosis.
Apoptosis in reperfusion
After 3 h of reperfusion, caspase-3 activity increased notably compared with the sham group (Figure 4) . With the actin cytoskeletal stabilizer Jasplakinolide (CI/R+JP group) caspase-3 activity tended to be lower than in the CI/R group. By contrast, both actin cytoskeleton disruptor agents, Swin A and Latrunculin, induced a significant increase in caspase-3 activity compared with the CI/R group. Caspase 3 activity increases was abolished when a cytoskeleton stabilizing agent had been used previously (CI/R+SwinA+JP group).
WI was associated with a significant increase in caspase-3 activity (WI+CI/R group). The addition of the stabilizer Jasplakinolide (WI+JP+CI/R group) reversed this effect.
DNA fragmentation by TUNEL detection after reperfusion also revealed differences between groups ( Figure 5 ), more TUNEL-positive cells being found in the CI/R group than in the sham group. No significant differences were observed with the administration of the stabilizing agent to the CI group (CI/R+JP).
The number of TUNEL-positive cells increased significantly with both disruptor agents (CI+LB+R and CI+SwinA+R groups). Jasplakinolide reversed the increase in apoptotic TUNEL-positive cells.
WI previous to cold ischemia produced an increase in the number of TUNEL-positive cells, which was again reversed by the use of Jasplakinolide. 
Discussion
This study provides new data indicating that cytoskeletal alterations occurring during different ischemic processes associated with kidney transplantation (cold ischemia, or cold ischemia with the additive effect of previous warm ischemia) are transformed into apoptosis after reperfusion.
Cytoskeleton derangement due to ischemia induces changes in cell morphology and function. 26, 27 The consequences of these alterations in renal tissue comprise abnormal tubular reabsorption and secretion, tubular obstruction and backleak of glomerular filtrate, 3 which directly affect the graft outcome. In the case of renal allografts from cadaveric M. Genescà et al. 
donors which have undergone previous WI injury, cytoskeletal alterations are associated with delayed graft function, and predispose the graft to acute or chronic rejection. 4, 5 In spite of the relationship between cytoskeletal alterations and the outcome of ischemic processes associated with transplantation procedures, there are no reports of a relation between cytoskeletal alterations and apoptosis in I/R. Since cytoskeletal fragmentation induces proapoptotic signals in a variety of experimental models and tissues [1] [2] [3] 28 and since apoptosis is associated with I/R injury in the kidney, 13 we studied whether there is a relationship between cytoskeletal alterations and apoptosis in kidney I/R injury.
To do so we used pharmacological compounds previously reported to be effective stabilizers or disruptors of the actin cytoskeleton. As disruptors we used two drugs with different modes of action (one, SwinA, severs actin filaments, while the other, LB, promotes actin depolymerization 19 ). The results indicate that these agents, at the tested doses, have a marked effect on F-actin distribution (Figure 1) . Jasplakinolide was used to study the effects of cytoskeleton stabilization. Since previous studies have found the action of this agent to be dose dependent 29 and report that it has a prevailing stabilizing effect at low doses, 21 Jasplakinolide appeared particularly well suited for our study. But in spite of its proven role as a cytoskeleton stabilizer, it has other undesired effects that make its use controversial. Previous studies indicate that JP competitively inhibits the binding of phalloidin to Factin, 30 which is the method used in our study to visualize the cytoskeleton. Others found no direct evidence that the two drugs compete for the same binding site 28 and moreover, reported that JP has better cell membrane penetration than phalloidin. 27 Still others have demonstrated that JP acts by inducing apoptosis through a caspase 3 dependent pathway. 31 Despite these hypothetical difficulties, our results support the claim that JP acts as a cytoskeleton stabilizer at the dose tested here (Figure 1 ), since all JP treated groups showed reversion of cytoskeletal disruption. This reversal was also observed in the groups in which disruption had previously been provoked by Swinholide, demonstrating Jasplakinolide's ability to counteract the effect of a disruptor of this kind. Moreover, we visualized the cytoskeleton with phalloidin without difficulty in any of the groups, including JP treated groups where the reversion of the disruption was clear.
Second, our results for parameters of apoptosis challenge previous reports: in our model, JP did not induce apoptosis but reversed the apoptosis provoked by previous cytoskeleton disruption.
In spite of our results, we cannot rule out the possibility that JP might induce apoptosis at higher doses or at other time points. Further studies are needed to confirm that it can be used generally as an anti-apoptotic agent in I/R procedures.
We proposed that the development of apoptosis in kidney reperfusion is dependent on actin cytoskeletal damage during prior preservation period. The direct F-actin cytoskeleton disruption by chemical disruptor agents administered before cold ischemic preservation increased the number of apoptotic cells and apoptotic parameters during reperfusion. Significant increases in active caspase-3 and fragmented-DNA detection were only found in reperfusion and were more pronounced when the animals had been previously treated with SwinA and LB (Figures 4 and 5) . When the stabilizing agent was administered concomitantly with a disruptor agent, the apoptosis increase was reversed, indicating that actin cytoskeleton derangement participates in caspase-3 activation during kidney I/R.
Several studies have reported that a key factor in the actin cytoskeleton's regulation of apoptosis is dynamic redistribution rather than cleavage. Morley et al. 32 showed in lymphocytes that alteration in the distribution of F-to G-actin affects both the execution phase and the early signal transduction pathways, leading to apoptosis. Nevertheless, the mechanism by which F-actin damage is involved in the onset of apoptosis remains to be elucidated.
Current evidence implicates DNase I as responsible for hydrolysis of DNA during apoptosis, and it is likely that disruption of the actin-DNase I complex results in activation of DNase I. The fact that the N-terminal fragment of gelsolin (N-gelsolin) disrupts the actin-DNase I interaction and that cofilin stabilises the actin-DNase I complex 33 suggest the involvement of these proteins in the cytoskeleton mechanism that regulates apoptosis. Haldar et al. 34 showed that drugs disrupting cytoskeletal integrity cause apoptosis via inactivation of Bcl-2, while other studies showed involvement of Rho family proteins in this apoptosis modulation. 35, 36 . Further studies are required to identify all the mechanism by which cytoskeletal alterations influences apoptosis in reperfusion.
It is known that WI induces rapid rearrangement of the actin cytoskeleton in proximal tubule cells. 26, 27 In agreement with previous results 8, 27 we found a strongly altered pattern in F-actin distribution after WI. Cold ischemia per se slightly perturbs the actin cytoskeleton, demonstrating a clear difference between the two models of I/R injury associated with kidney transplant. This difference is not detected in apoptotic parameters during the preservation period but a marked increase in apoptosis is detected during reperfusion; positive TUNEL staining was found in the cortical tubules. Some of these tubules showed homogeneous staining; we cannot rule out the possibility that some unspecific staining for necrotic cells may have occurred in kidneys subjected to previous WI. In fact, acute tubular necrosis is one of the typical deleterious conditions associated with WI in kidneys from non-heart beating donors. 37 In any case, in our study, administration of JP prior to WI reversed the effects on caspase-3 activity, suggesting that cytoskeleton alterations induced by WI are able to induce apoptosis by caspase-3 activation at reperfusion.
Conclusion
In conclusion, disruption of the actin cytoskeleton during ischemic conditions associated with kidney preservation induces apoptosis upon reperfusion through caspase-3 activation. The present findings suggest that the stabilization of the actin cytoskeleton to minimize apoptosis is an interesting and novel target for therapeutic interventions in renal transplantation.
Further research is needed to evaluate the impact of the cytoskeleton and apoptosis changes on renal function and graft outcome and to develop new pharmacological compounds better suited for stabilizing the cytoskeleton.
